



PATENT CLAIMS


1. Use of an inhibitor of KRAS oncogene activation in the manufacture of a medicament for treating KRAS-mutated proliferative disorder or genetic disorder, wherein the inhibitor of KRAS oncogene activation is a flavagline derivative, the flavagline derivative is FL3, FL10, FL13, FL15, FL19, FL23, FL32, FL37, FL40, FL42, or IMD-26260 having the following structure:
































2. The use according to claim 1, wherein RAS signalling involves a mutated KRAS gene.

3. The use according to claim 2, wherein the KRAS gene contains a G12V, G12C, G12D, G13C, G13D, G13S, Q61 H, Q61 R, and/or Q61 K mutation.


4. An in vitro or ex vivo method of specifically inhibiting proliferation of a cell population by targeting KRAS, the method comprising the step of contacting the cell population with a flavagline derivative, the flavagline derivative is FL3, FL10, FL13, FL15, FL19, FL23, FL32, FL37, FL40, FL42, or IMD-26260 having the following structure:.









FL13




FL15




FL19




FL23




FL32




FL37



FL40



FL42




IMD-26260


.

5. The method according to claim 4, wherein inhibition of the proliferation of the cell population is measured as a decrease in cell viability of the cell population.


6. Use of a pharmaceutical composition in the manufacture of a medicament for treating a disease in which RAS signaling is pathologically involved, the pharmaceutical composition comprising a compound, which is a flavagline derivative selected from FL3, FL10, FL13, FL15, FL19, FL23, FL32, FL37, FL40, FL42, or IMD-26260 having the following structure:




FL3




FL10




FL13




FL15




FL19




FL23



FL32



FL37



and a pharmaceutically acceptable vehicle, diluent, adjuvant or excipient.

7. The use according to claim 6, wherein the disease is a KRAS-mutated proliferative disorder or genetic disorder.

8. The use according to claim 6, wherein the disease is a neoproliferative disease, cancer, RASOpathy or craniofacial syndrome.

9. The use according to claim 8 , wherein the cancer is colorectal cancer, lung cancer, hematological cancer, MYH associated polyposis, bladder cancer, melanoma, acute myeloid leukemia (AML), or pancreatic cancer.

10. The use according to claim 6, wherein RAS signalling involves a mutated KRAS gene.

11. The use according to claim 10, wherein the mutated KRAS gene contains a G12V, G12C, G12D, G13C, G13D, G13S, Q61 H, Q61 R, and/or Q61 K mutation.